The efficacy of adalimumab in the treatment of hidradenitis suppurativa

• Main Authors: Ali Balevi, Pelin Ustuner, Mustafa Özdemir
• Format: Article
• Language: English
• Published: Dicle University Medical School 2018-03-01
• Series: Dicle Medical Journal
• Subjects: Adalimumab; eccrine glands
• Online Access: http://www.diclemedj.org/upload/sayi/68/Dicle%20Med%20J-03282.pdf

Objectives:Hidraadenitissuppurativa is seen as a result of the occlusion, constriction and bacterial infection of the apocrine glands in bilateral axillas, submammarian areas, neck, inguinal regions, flexural surfaces of the thighs and anogenital areas. Among the biological agents adalimumab is a recombinant human IgG1 monoclonal antibody; TNF-α antagonist approved to be used in the treatment of hidradenitissuppurativa. Methods: In this study, 12 patients resistant to conventional treatments with moderate severity, Hurley stage 2 or 3 were started subcutaneous adalimumab treatment. The disease activities upon the hidraadenitissuppurativa, clinical severity index and life quality index of the patients were examined both before and 1 year after the treatment. Results: Twelve patients were recruited. In the examination of the hidraadenitissuppurativa clinical severity scores, significant clinical responses were noted in 9 (75%) patients. While the mean value of the life quality index was 14.4±6.9 before the treatment, it was determined to be significantly decreased to 4.3±3.8 after the treatment. Conclusion: We concluded that adalimumab; the unique biological agent approved to be used in the treatment of treatment-resistant, moderate-severe hidraadenitissuppurativa is efficient and safe in similar ratios with the previous clinical studies in the literature.